XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Auction Rate Securities | 3 Months Ended
--- | ---
Sep. 30, 2016
Text Block [Abstract] |
Auction Rate Securities | 5. Auction Rate Securities Our ARS investments, which are included in non-current other assets in the condensed consolidated balance sheets, have failed to settle in auctions beginning in 2007. These investments are not liquid, and in the event we need to access these funds, we will not be able to do so without a loss of principal, unless redeemed by the issuers or a future auction on these investments is successful. As there are currently no active markets for our various failed ARS investments, we have estimated the fair value of these investments as of September 30, 2016 using a trinomial discounted cash flow analysis. The analysis considered, among others, the following factors:
| • | the collateral underlying the security investments;
| • | the creditworthiness of the counterparty;
| • | the timing of expected future cash flows;
| • | the probability of a successful auction in a future period;
| • | the underlying structure of each investment;
| • | the present value of future principal and interest payments discounted at rates considered to reflect current market conditions;
| • | a consideration of the probabilities of default, a successful future auction, or redemption at par for each period; and
| • | estimates of the recovery rates in the event of default for each investment.
When possible, our failed ARS investments were compared to other observable market data or securities with similar characteristics. Our estimate of the fair value of our ARS investments could fluctuate from period to period depending on future market conditions. We have ARS investments with a fair value of $7.1 million maturing in fiscal year 2018 and $1.5 million fair value with no maturity date. All of our ARS investments are below investment grade. The ARS investments we held as of September 30, 2016, including the original cost basis, other-than-temporary impairment included in retained earnings, new cost basis, unrealized gain, and fair value, consisted of the following (in millions):
|  | Original Cost Basis |  |  | Other-than- temporary Impairment in Retained Earnings |  |  | New Cost Basis |  |  | Unrealized Gain |  |  | Fair Value |
Credit linked notes |  | $ | 7.5 |  |  | $ | (1.9 | ) | (1) | $ | 5.6 |  |  | $ | 1.5 |  |  | $ | 7.1 |
Preferred stock |  |  | 5.0 |  |  |  | (5.0 | ) |  |  | - |  |  |  | 1.5 |  |  |  | 1.5 |
Total ARS |  | $ | 12.5 |  |  | $ | (6.9 | ) |  | $ | 5.6 |  |  | $ | 3.0 |  |  | $ | 8.6 |
(1) | Other-than-temporary impairment in retained earnings is partially offset by cumulative accretion of $4.7 million on non-current investments. Accretion is reclassified from accumulated other comprehensive income and recorded in the condensed consolidated statements of income as non-cash interest income.
The ARS investments we held as of June 30, 2016, including the original cost basis, other-than-temporary impairment included in retained earnings, new cost basis, unrealized gain, and fair value, consisted of the following (in millions):
|  | Original Cost Basis |  |  | Other-than- temporary Impairment in Retained Earnings |  |  | New Cost Basis |  |  | Unrealized Gain |  |  | Fair Value |
Credit linked notes |  | $ | 7.5 |  |  | $ | (2.2 | ) | (1) | $ | 5.3 |  |  | $ | 1.8 |  |  | $ | 7.1 |
Preferred stock |  |  | 5.0 |  |  |  | (5.0 | ) |  |  | - |  |  |  | 1.5 |  |  |  | 1.5 |
Total ARS |  | $ | 12.5 |  |  | $ | (7.2 | ) |  | $ | 5.3 |  |  | $ | 3.3 |  |  | $ | 8.6 |
(1) | Other-than-temporary impairment in retained earnings is partially offset by cumulative accretion of $4.4 million on non-current investments. Accretion is reclassified from accumulated other comprehensive income and recorded in the condensed consolidated statements of income as non-cash interest income.
We have accounted for our ARS investments as non-current as we are not able to reasonably determine when the ARS markets will recover or be restructured. Based on our ability to access our cash and cash equivalents, our expected operating cash flows, and our other sources of cash, we do not intend to sell the ARS investments and it is not more likely than not that we will be required to sell our ARS investments before the recovery of the amortized cost basis.

X
- Definition The entire disclosure for investments and other noncurrent assets. + References No definition available. + Details
Name: | us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration